Overview of the Three Parts of the Phase-1 First-in-human Study on Flubentylosin.
QD; once daily; PK: pharmacokinetics* 800 mg (8 ´ 100 mg capsule) planned in protocol, adjusted to 1000 mg based on pharmacokinetic and safety results of previous groups in Part 1** 1200 mg (12 ´ 100 mg capsule) planned in protocol, changed to 400 mg with confinement extended from 5 to 12 days and additional laboratory test